Communiqués Ultragenyx Pharmaceutical Inc.

Actions

RARE

US90400D1081

Produits pharmaceutiques

Temps réel estimé Cboe BZX 21:59:04 18/08/2026			Varia. 5j.	Varia. 1 janv.
25,47 ^USD	-2,53%		-5,34%	+10,96%

05/08	Ultragenyx Pharmaceutical : la perte se réduit au deuxième trimestre avec la hausse du chiffre d'affaires ; les prévisions pour 2026 sont confirmées	MT
04/08	Transcript : Ultragenyx Pharmaceutical Inc., Q2 2026 Earnings Call, Aug 04, 2026

Communiqués

04/08	Ultragenyx: Q2 Earnings Snapshot	AQ
04/08	Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update	GL
28/07	Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update	GL
28/07	Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update	AQ
24/07	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
08/07	Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact	GL
22/06	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
19/06	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
03/06	Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference	GL
01/06	Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm	NE
22/05	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
06/05	Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference	GL
05/05	Ultragenyx: Q1 Earnings Snapshot	AQ
05/05	Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update	GL
29/04	Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update	GL
27/04	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
24/04	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
08/04	RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026	NE
05/04	RARE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026	NE
04/04	Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE	BU
03/04	DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026	PR
02/04	Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)	GL
31/03	Ultragenyx Announces FDA Clearance of Investigational New Drug Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy	AQ
31/03	RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026	NE
30/03	NASDAQ: RARE CLASS ACTION NOTICE: Berger Montague Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire About a Securities Fraud Class Action	NE